Lorazepam extended-release - Edgemont Pharmaceuticals

Drug Profile

Lorazepam extended-release - Edgemont Pharmaceuticals

Alternative Names: EDG-004

Latest Information Update: 27 Jul 2016

Price : $50

At a glance

  • Originator Edgemont Pharmaceuticals
  • Class Antiemetics; Anxiolytics; Benzodiazepinones; Hypnosedatives; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Generalised anxiety disorder

Highest Development Phases

  • Phase III Generalised anxiety disorder

Most Recent Events

  • 31 May 2016 Edgemont Pharmaceuticals completes a phase III trial for Generalised anxiety disorder in USA (NCT02305797)
  • 01 Jan 2015 Phase-III trials in Generalised anxiety disorder in USA (unspecified route) (NCT02305797)
  • 08 Dec 2014 Lorazepam extended-release is available for licensing in World as of 08 Dec 2014. http://edgemontpharma.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top